Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes. I saw you there yesterday.
I will try later. Thanks.
Talking about the year of execution, the peer reviews by .........
Where are they?
Hope we see them before the year end.
.
you must have changed your mind within a week. Or chart did.
dyp Friday, 10/11/19 09:51:14 AM
Re: None 0
Post # 214054 of 215391
absolutely.
extremely bullish
pattern
confirmed.
no place to go
but
up.
PUMP & DUMP!
What would happen to pps if we hear that news one morning?
Just a mid-week fantasy. : )
Thank you for your time. Appreciated.
Nidan,Xena & Doc
Thank you. I will accumulate more and pass them to Xena.
I can not imagine any patient to lose their privilege because of not following rules of the clinical trials. It's not a crime but what do I know.
A comment on Facebook: 21 hrs ago
After 20 years, wow. What a beautiful thing, Havana! Great job!!! If these are results from the Anavex trial their is going to be many more videos like this! Congratulations!!!
WOW!
Help! Can you help on acronym for this board?
Just a couple for a person I ask, anyone?
Thank you in advance.
AGM
CRO
CRL
CTN
EHR
EMA
GCP
HREC
ICH
IND
IRB
MAA
NDA
TGA
Absolutely Amazing!!!!
We Got This!
AVXL$$$$
We all know that. Why did you warn us? wHY? wHY? wHY? wHY? wHY?
Who are selling? Certainly not retail. What’s going on behind
I agree that I’ve never been more confident in Anavex.
.
Good advise but hard to believe.
Are you saying the stock price rode 2 years after fda approval?
News-
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study
NEW YORK – September 27, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today presented preliminary clinical efficacy data from the PK cohort (Part A) of the U.S. Phase 2 Rett syndrome clinical trial ANAVEX®2-73-RS-001.
“The data from the PK cohort (Part A, n=6) is very encouraging because of the (1) magnitude of change (large to very large effect sizes: Cohen’s d: RSBQ Total 1.47; Cohen’s d: Glutamate 1.11), (2) the efficacy signal on both caregiver- and clinician-based measures of severity and correlations with key biomarker related to disease pathogenesis (Glutamate), (3) the short duration of treatment with ANAVEX®2-73 (blarcamesine), (4) the relatively low dose, (5) the older age of participants, and (6) the clinical significance (RSBQ-CGI-I correlations),” said Walter E Kaufmann, MD, Principal Investigator of the study and Chief Medical Officer of Anavex. “The randomized, double-blind, placebo-controlled study (Part B, n=15) is currently ongoing.”
This is one of three clinical studies in Anavex’s Rett Syndrome Program: U.S. RTT (ANAVEX®2-73-RS-001), AVATAR (ANAVEX®2-73-RS-002) and EXCELLENCE (ANAVEX®2-73-RS-003).
Principal Investigator of the study and Chief Medical Officer of Anavex, Walter E Kaufmann, MD presented the data. The presentation will be available at www.anavex.com.
PK cohort (Part A) ranging in age from 18 to 36 years, who completed the pharmacokinetic (PK) part of the study received a low dose of approx. 5 mg daily oral liquid dose of ANAVEX®2-73 (blarcamesine) for 7 weeks. Efficacy evaluations took place at Baseline (Week 0), Week 4 and Week 7.
In addition to the significant improvements of the two global efficacy endpoints, the Rett Syndrome Behaviour Questionnaire (RSBQ) Total score and the Clinical Global Impression – Improvement (CGI-I), the RSBQ Hand Behaviours and the RSBQ Breathing Abnormalities improved during the trial. Efficacy signals on both caregiver- & clinician-based measures of severity correlated with a key biomarker related to disease pathogenesis (Glutamate). The biomarker correlation was also significant with the improvement in CSHQ (Children's Sleep Habits Questionnaire).[1]
Christopher U Missling, PhD, President and Chief Executive Officer of Anavex stated, “We are intrigued by the biomarker correlation with the efficacy measures for ANAVEX®2-73 (blarcamesine) in patients with Rett syndrome and we are currently proceeding with Part B of the study. In addition to Rett syndrome[2], Anavex has ongoing clinical development programs for ANAVEX®2-73 (blarcamesine) for the treatment of Alzheimer’s disease[3] and Parkinson’s disease dementia[4].”
About Rett Syndrome
and the bonus-
These preliminary results will soon be submitted for publication in a peer-reviewed journal, according to the company.
meds4life, Thank you for the link.
I know it has been posted but I can not help but repeating as these messages as they are so strong...........
Looking forward to hearing the 6th European Rett Syndrome Conference on Friday!
------------------------------------------------------------------
Preliminary clinical data from a Phase 2 trial testing Anavex-2-73 suggest the investigational therapy is effective and safe for the treatment of Rett syndrome.
Prior to treatment, the average RSBQ score was 50. After seven weeks on Anavex-2-73, the average score decreased to 35, suggesting a lessening of symptoms. CGI-I scores were significantly correlated with RSBQ scores, suggesting similar improvement; Anavex did not specify values.
Additionally, after seven weeks of treatment, blood levels of the neurotransmitter glutamate decreased significantly, while levels of another neurotransmitter, GABA, or gamma-aminobutyric acid, increased significantly. A neurotransmitter is a chemical molecule that allows nerve cells to communicate. In Rett syndrome, there tend to be abnormally high glutamate levels and abnormally low GABA levels. As such, these results suggest a “balancing” of neurotransmitter levels.
Wasn’t he supposed to speak/present somewhere after market today?
Oh I'm sorry. I thought I was replying to message #210848.
.
Out all day and missed it. 159,176 shares buy at one shot.
= $560,000
Amazing!!
Go AVXL$$$!!!
Swing trader’s dream.
USELESS
Thanks for the info.
India stocks performed not so good last 18 month.
Hope they do better coming years.
Salute! Appreciate your time and effort having introduced AVXL to that many people.
Who has kept pps up with painting at the end of day?
Is mission finished yet?
so cheap
Oh I didn't want to go on a limb but you did. lol
Guess I need to dream harder.
GO AVXL!!
Can I translate what you were saying into $$$ - that is $1000/share?
Just trying
Yes I’m happy for 2nd day in green with double of the average volume on a good news which hasn’t happened for AVXL.
AVXL$$$
Because he is a swinger.
endless human mistakes I hate it, sigh.
thank you for correction.
Found your comment interesting but possible in reality.
Glad they are not the only prospect buyer.
Where did you read, link?
Just kidding as I know you cannot find it.
It is A2-37 and for Alzheimer’s, Parkinson’s, Rett syndromes and other more CNS diseases.
And if it works and approved ssp will go up 100x or mor.
You are lucky to find it at this moment.
GLTU
Not reccomendation
Bottom at $106?
Can you elaborate it little more?
Pps is almost doubled in premarket with high volume: $48x 170k = $8 mil
Nice poster!
Nice story. I like the term you used - "market acceptance phase".
I don believe when posters say pps will stay where it is till we get trial data in 20xx.
Appreciate your contribution on the board.
GLTU
That’s very true. Their parents will even be able to tell if A273 works or not clearly.
Not a good analogy as each of them run AD clinical trial sites for 2-73 at their respective institutions.
They all hear,see and know the effects of A237 IMHO.
Thank you! You did it again.
This tells all: Beyond Amyloid -The sigma 1 receptor
And about 3 speakers including Dr.Missling, me think there are enough reasons to believe their appearances are related. : )
GLTU
yea the current holders believe in something but we don't see any other's big buys coming in
in spite of high level developments in GSE this year. PPS is same as in Feb.
If it were in 2012 with these kind news pps is probably @ $12 now. I saw $6 in 2012(not sure for year).
It wasn't diluted, was it? What changed, what am I not seeing?
Can not tell if you are serious or being sarcastic- hard to tell on this one. Lol